Glenmark Pharma rises 1% on USFDA approval for Teriflunomide tablets

0
86

Glenmark Pharma rises 1% on approval for Teriflunomide tablets

Share price of Glenmark Pharma rose 1.5 percent in the early trade after company received a USFDA approval for Teriflunomide tablets.

Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration(USFDA) for Teriflunomide tablets ,7 mg & 14 mg, a generic version of Sanofi- Aventis US,LLC.

With this approval, Glenmark is eligible for  180 days of shared generic drug exclusivity for Teriflunomide Tablets ,7 mg &14 mg.

Company’s current portfolio consists of 142 products authorized for distribution in the US marketplace and 57 ANDA’s pending approval with the US FDA.

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplements and accelerate the growth of its existing pipeline and portfolio, company said in release.

Glenmark Pharma rises 1% on approval for Teriflunomide tablets

–Sharing is Caring–

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here